• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Jounce Therapeutics Confirms Receipt of Unsolicited Proposal from Concentra Biosciences

    3/14/23 9:00:00 PM ET
    $JNCE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNCE alert in real time by email

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

    CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the "Board") of Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today confirmed that Concentra Biosciences, LLC ("Concentra"), of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal ("the Proposal") to acquire 100% of the equity of Jounce. According to the Schedule 13D filed today with the U.S. Securities and Exchange Commission ("SEC") disclosing the Proposal, Tang Capital1 is currently approximately a 10.2% shareholder of Jounce.

    The Proposal consists of $1.80 in cash per share plus a contingent value right ("CVR") representing the right to receive 80% of the net proceeds payable from any license or disposition of certain of Jounce's legacy programs2 (the "CVR Products"). The proposal is subject to limited confirmatory due diligence and is based on the availability of at least $130 million of cash and cash equivalents at closing, net of any tail and closing costs.

    On February 23, 2023, the Company announced a recommended business combination with Redx Pharma (AIM: REDX) ("Redx") via a proposed all share merger transaction (the "Business Combination"). The transaction is anticipated to be completed during the second quarter of 2023, subject to necessary regulatory and shareholder approvals. Shareholders are advised that no action is necessary at this time.

    The Board is committed to acting in the best interests of all shareholders, consistent with its fiduciary duties. A further announcement will be made in due course.

    About Jounce Therapeutics

    Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. For more information, please visit www.jouncetx.com.

    For further information, please contact:

    Jounce Therapeutics, Inc

    Kim Drapkin

    [email protected]
    T: +1-857-259-3840
      
    Cowen (Financial Adviser to Jounce)T: +1-646-562-1010
    Tanya Joseph / Erik Schuchard / Giles RoshierT: +44 (0)203 011 0460
      
    Stern Investor Relations (Adviser to Jounce) 
    Julie SeidelT: +1-212-362-1200
      
    Longacre Square Partners (Adviser to Jounce)

    Dan Zacchei / Rebecca Kral

    [email protected]
     

    Important notices

    Cowen Execution Services Limited ("Cowen"), which is authorised and regulated in the United Kingdom by the FCA, is acting exclusively as financial adviser to Jounce and no one else in connection with the Business Combination and/or the Proposal and will not be responsible to anyone other than Jounce for providing the protections afforded to clients of Cowen nor for providing advice in relation to the Business Combination, the Proposal, the contents of this Announcement or any other matters referred to in this Announcement. Neither Cowen nor any of its affiliates, nor any of Cowen's and such affiliates' respective members, directors, officers, controlling persons or employees owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, consequential, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Cowen in connection with the Business Combination, the Proposal, this Announcement, any statement contained herein or otherwise.Overseas Shareholders

    The release, publication or distribution of this Announcement in or into certain jurisdictions other than the United Kingdom may be restricted by law. Persons who are not resident in the United Kingdom or who are subject to other jurisdictions should inform themselves of, and observe, any applicable requirements.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of US federal securities laws, as amended, including, without limitation, statements regarding beliefs about and expectation for the anticipated timing of the closing of the Business Combination and the Company's intention to make additional announcements and filings. The words "estimates," "expects," "continues," "intends," "plans," "anticipates," "targets," "may," "will," "would," "could," "should," "potential," "goal," and "effort" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this report are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this report, including, without limitation, the determinations made by Jounce's board of directors following its evaluation of the Proposal; actions of Redx in response to any discussions with Concentra; the results of discussions with Concentra; the impact of actions of other parties with respect to any discussions and the potential consummation of the proposed transaction with Redx; the outcome of any legal proceedings that could be instituted against Jounce or its directors related to the discussions or the Cooperation Agreement with Redx; changes in the proposal from Concentra; the risk that the transactions contemplated by the Business Combination may not be completed in a timely manner, or at all, which may adversely affect Jounce's business and the price of its common stock; the failure to satisfy all of the closing conditions of the transactions contemplated by the Cooperation Agreement with Redx, including the requisite approval by Jounce's shareholders; the occurrence of any event, change or other circumstance that could give rise to the termination of the Cooperation Agreement with Redx; the effect of the announcement or pendency of the transactions contemplated by the Business Combination on Jounce's business, and operating results; risks that the transactions contemplated by the Business Combination may disrupt Jounce's current plans and business operations; risks related to the diverting of management's attention from Jounce's ongoing business operations; the outcome of any legal proceedings that may be instituted against Jounce related to the Cooperation Agreement with Redx, the Business Combination and the transactions contemplated thereby; general economic and market conditions and the other risks identified in the Company's filings with the SEC, including its most recent Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 10, 2023 and subsequent filings with the SEC. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the Business Combination and/or Jounce, Jounce's ability to successfully complete the Business Combination and/or realize the expected benefits from the Business Combination. Jounce cautions investors not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Jounce disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this report represent Jounce's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

    Additional Information and Where to Find It

    In connection with the proposed Business Combination, a meeting of the shareholders of Jounce will be announced as promptly as practicable to seek shareholder approval in connection with the proposed transaction. Jounce intends to file relevant materials with the SEC, including the filing by of a preliminary and definitive proxy statement relating to the proposed transaction. The definitive proxy statement will be mailed to the Company's shareholders. This press release is not a substitute for the proxy statement.

    BEFORE MAKING ANY DECISION, THE COMPANY'S SHAREHOLDERS ARE URGED TO CAREFULLY READ THE PRELIMINARY AND DEFINITIVE PROXY STATEMENTS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED BUSINESS COMBINATION OR INCORPORATED BY REFERENCE INTO THE PROXY STATEMENT WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED BUSINESS COMBINATION.



    Any vote in respect of resolutions to be proposed at the Company's shareholder meeting to approve the proposed Business Combination or other responses in relation to the proposed transaction should be made only on the basis of the information contained in the Company's proxy statement. The Company's shareholders will be able to obtain a free copy of the proxy statement and other related documents (when available) filed by the Company with the SEC at the website maintained by the SEC at www.sec.gov or by accessing the Investor Relations section of the Company's website at https://www.jouncetx.com.

    No Offer or Solicitation

    The information contained in this press release is for information purposes only and is not intended to and does not constitute, or form any part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or dispose of any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the Business Combination or otherwise, nor shall there be any sale, issuance, subscription or transfer of securities in any jurisdiction in contravention of applicable law or regulation. In particular, this press release is not an offer of securities for sale in the United States. No offer of securities shall be made in the United States absent registration under the Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from, or in a transaction not subject to, such registration requirements. Any securities issued as part of the Business Combination are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the Securities Act and any securities issued as part of the proposed merger contemplated in connection with the Business Combination are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 4(a)(2) of the Securities Act and the rules promulgated thereunder. The Business Combination will be made by means of a Scheme Document and the Merger Agreement to be published by Redx in due course, or (if applicable) pursuant to an offer document to be published by the Company, which (as applicable) would contain the full terms and conditions of the Business Combination. Any decision in respect of, or other response to, the Business Combination, should be made only on the basis of the information contained in such document(s).

    Participants in the Solicitation

    The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the Company's shareholders in connection with the proposed Business Combination. Information regarding the Company's directors and executive officers is contained in the Company's Definitive Proxy Statement for its 2022 Annual Meeting of Shareholders filed with the SEC on April 28, 2022. Other information regarding the participants in the solicitation of proxies in respect of the transactions contemplated by the Business Combination or the transactions contemplated by the Proposal, as applicable, including a description of their respective direct or indirect interests, by security holdings or otherwise, will be included in any registration statement, prospectus, proxy statement and other relevant materials to be filed with the SEC if and when they become available. These documents (when available) may be obtained free of charge from the SEC's website at www.sec.gov or by accessing the Investor Relations section of the Company's website at https://ir.jouncetx.com/sec-filings.

    Publication on website

    A copy of this Announcement shall be made available subject to certain restrictions relating to persons resident in Restricted Jurisdictions on Jounce's website at https://jouncetx.com/recommended-offer/ by no later than 12 noon (London time) on the Business Day following the date of this Announcement. For the avoidance of doubt, the contents of the website are not incorporated into and do not form part of this Announcement.


    1 Includes Tang Capital Partners, LP, Tang Capital Management, LLC and Kevin Tang.

    2 JTX-8064, vopratelimab, pimivalimab, JTX-1484 and JTX-2134.



    Primary Logo

    Get the next $JNCE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JNCE

    DatePrice TargetRatingAnalyst
    5/11/2022$15.00 → $7.00Outperform → Neutral
    Robert W. Baird
    5/6/2022$15.00 → $20.00Outperform → Strong Buy
    Raymond James
    3/16/2022$17.00Outperform
    SMBC Nikko
    2/4/2022Market Perform → Outperform
    Cowen & Co.
    11/5/2021$10.00 → $15.00Outperform
    Raymond James
    9/14/2021$10.00Market Perform → Outperform
    Raymond James
    More analyst ratings

    $JNCE
    Leadership Updates

    Live Leadership Updates

    See more
    • Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors

      CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of former chief executive officer of Constellation Pharmaceuticals and former Jounce chief business officer, Jigar Raythatha, to its board of directors. "It's incredibly exciting to welcome Jigar to our board of directors. Not only does Jigar bring over 20 years of biotechnology industry experience, but he also comes with a unique position as an early employee of the company at its inception," said Richard Murray, Ph.D., chief executive offic

      9/15/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Dmitri Wiederschain, Ph.D., as Chief Scientific Officer. "The addition of Dmitri to the Jounce team comes at an exciting juncture in our company development," said Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics. "Dmitri brings a broad knowledge of contemporary immuno-oncology approaches, tumor immunology and cancer biology. His expertise with preclinical target discovery and first-in-human research will

      4/12/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors

      CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Luisa Salter-Cid, Ph.D., to its board of directors. “We are thrilled to welcome Luisa to our board of directors,” said Perry Karsen, chairman of the board of Jounce Therapeutics. “Luisa brings over 20 years of experience in the healthcare industry, specifically in immunology and immuno-oncology, and we look forward to the unique and valuable perspective that her strategic leadership will bring to Jounce.” Dr. Salter-Cid currently serves a

      2/12/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Concentra Biosciences, Llc

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/5/23 4:38:21 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Tang Kevin C

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/5/23 4:37:26 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Concentra Biosciences, Llc claimed ownership of 36,367,727 shares

      3 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/5/23 4:35:30 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jounce Therapeutics Announces Closing of Tender Offer

      CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Concentra Biosciences, LLC ("Concentra"), through its wholly owned subsidiary Concentra Merger Sub, Inc. ("Concentra Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of the common stock of Jounce for $1.85 per share in cash plus a non-tradeable contingent value right (a "CVR") per share. The $1.85 per share upfront consideration represents a premium of approximately

      5/3/23 8:35:17 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Redx Pharma plc ("Redx") have agreed to terminate their proposed business combination following the decision by Jounce's Board of Directors to withdraw the recommendation for the all-share merger transaction with Redx (the "Redx Business Combination"). Jounce's decision was based upon the receipt of an unsolicited proposal from Concentra Biosciences, LLC ("Conc

      4/3/23 2:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC ("Concentra") will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right (the "CVR"). The $1.85 per share upfront con

      3/27/23 9:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Jounce Therapeutics Inc. (Amendment)

      SC 13G/A - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/14/24 8:50:07 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Jounce Therapeutics Inc.

      SC 13G - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/9/24 4:05:34 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jounce Therapeutics Inc. (Amendment)

      SC 13G/A - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/2/24 12:28:25 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    SEC Filings

    See more

    $JNCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $JNCE
    Financials

    Live finance-specific insights

    See more
    • SEC Form 15-12G filed by Jounce Therapeutics Inc.

      15-12G - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/15/23 7:40:24 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Jounce Therapeutics Inc.

      EFFECT - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/5/23 12:15:08 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Jounce Therapeutics Inc.

      EFFECT - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/5/23 12:15:07 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Jounce Therapeutics from Outperform to Neutral and set a new price target of $7.00 from $15.00 previously

      5/11/22 6:18:27 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics upgraded by Raymond James with a new price target

      Raymond James upgraded Jounce Therapeutics from Outperform to Strong Buy and set a new price target of $20.00 from $15.00 previously

      5/6/22 7:22:10 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SMBC Nikko initiated coverage on Jounce Therapeutics with a new price target

      SMBC Nikko initiated coverage of Jounce Therapeutics with a rating of Outperform and set a new price target of $17.00

      3/16/22 7:50:25 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redx and Jounce Announce Recommended Business Combination

      Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to include discovery projects from both Redx and Jounce Combined group to be called Redx Inc. listed on Nasdaq under the ticker REDX and led by Redx CEO Lisa Anson with cash runway into H2 2025 ALDERLEY PARK, United Kingdom and CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) today announce an unanimously recommended Business Combination of the

      2/23/23 2:30:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Reports Third Quarter 2022 Financial Results

      - INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress - - SELECT randomized trial of pimivalimab +/- vopratelimab phase 2 data at ESMO-IO Annual Congress - - Two preclinical posters on JTX-1484 and LILRB family at SITC 2022 - - Ended the quarter with $130.3 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the third quart

      11/10/22 7:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022

      CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022. Jounce Therapeutics' management team will host a webcast and live conference call at 8:00 a.m. ET. Conference Call and WebcastTo access the conference call, please register here and please be advised to do so at least 10 minutes prior to joining the call. The live webcast can be accessed under "Events & Presentations" in the Investors and Me

      10/27/22 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care